BeOne Medicines AG (ONC)

Market Cap	37.69B
Revenue (ttm)	5.00B
Net Income (ttm)	33.00M
Shares Out	110.66M
EPS (ttm)	0.29
PE Ratio	1,142.18
Forward PE	75.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,471
Open	342.66
Previous Close	340.64
Day's Range	337.00 - 342.97
52-Week Range	170.99 - 385.22
Beta	0.46
Analysts	Strong Buy
Price Target	369.50 (+8.48%)
Earnings Date	Nov 6, 2025

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Financial Performance

In 2024, BeOne Medicines AG's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.

Financial numbers in CNY

Analyst Summary

According to 12 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $369.5, which is an increase of 8.48% from the latest price.

Price Target

$369.5

(8.48% upside)

Analyst Consensus: Strong Buy